EXACT Therapeutics
Amir Snapir has PhD from the University of Turku, Finland and MD from the University of Tel Aviv, Israel. He has extensive experience in global clinical development of novel therapeutics, combined with extensive international regulatory experience. Dr Snapir also has years of experience in business collaborations, alliances and product co-developments. His earlier positions include CMO of PCI Biotech, where he was responsible for the clinical development of drug-device combination product candidates, and leader of clinical pharmacogenomics and clinical development leader in Oncology at Orion Pharma.
This person is not in any offices
EXACT Therapeutics
1 followers
EXACT Therapeutics is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT®sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.